Summit Corp. forms advisory board to aid development of drug

Summit Corp., an AIM-listed drug discovery and development company, has formed an advisory board to support the scientific and clinical development of its utrophin modulator programme for the treatment of the fatal genetic disease Duchenne Muscular Dystrophy (DMD).

Summit Corp., an AIM-listed drug discovery and development company, has formed an advisory board to support the scientific and clinical development of its utrophin modulator programme for the treatment of the fatal genetic disease Duchenne Muscular Dystrophy (DMD).

The board will be made up of six world-renowned scientists and clinicians with expertise in the field of neuromuscular diseases, and particularly DMD.

"We are absolutely delighted to have brought together these eminent thought leaders in neuromuscular diseases to form a world-class Advisory Board that will support our DMD programme," commented Glyn Edwards, Chief Executive Officer of Summit.

"Their expertise brings a deep insight into the disease and will provide invaluable input into future patient clinical trials to support the progression of our utrophin modulation programme, including our lead candidate SMT C1100."

Shares in the company have fallen almost 30% in the year-to-date, equal to 1.88p.

NR

Recommended

Broker safety – your questions answered
Investment strategy

Broker safety – your questions answered

Cris Sholto Heaton answers more of your questions about the safety of stockbroker accounts
25 Mar 2020
How demographics affects stock valuations
Investment strategy

How demographics affects stock valuations

New research suggests that stock and bond valuations are driven by the age of the population – at least in the US.
24 Feb 2020
Do you own shares in Sirius Minerals? Here’s what you need to do now
Stocks and shares

Do you own shares in Sirius Minerals? Here’s what you need to do now

Mining giant Anglo American has proposed a cash takeover of Yorkshire-based minnow Sirius Minerals. Unhappy shareholders must decide whether to accept…
20 Feb 2020
Why investors should be “cautiously bullish” for 2020
Stockmarkets

Why investors should be “cautiously bullish” for 2020

Analysts have been out in force making rosy predictions for stockmarkets in 2020, but while there is certainly a case for optimism, investors should r…
17 Jan 2020

Most Popular

Investors are shunning UK stocks – but they might regret that in a year’s time
UK stockmarkets

Investors are shunning UK stocks – but they might regret that in a year’s time

There are a number of reasons why investors aren't buying UK stocks, says John Stepek. But they may want to rethink that strategy.
29 Sep 2020
Are we really in a stockmarket bubble?
US stockmarkets

Are we really in a stockmarket bubble?

The rise of “cash shell” companies, sky-high valuations – everything seems to point to a stockmarket bubble. But all may not quite be as it appears, s…
28 Sep 2020
Two commodities that could lie at the heart of the next resources bubble
Energy

Two commodities that could lie at the heart of the next resources bubble

Commodities tend to move in cycles. And if you can identify early on which ones are about to surge in demand, you can profit handsomely. Dominic Frisb…
30 Sep 2020